Payment overview · 2025
General Payments
$445.73
24 reported records · 11 companies
Healthcare provider profile · identity verified
Robert David Sapp, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPENCER, TN · NPI 1982705836
Verified facts
What the public records show
CMS Open Payments records show Robert David Sapp, MD received $445.73 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.52 | 31.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.52 | 16.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.75 | 11.8% | 3 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $30.63 | 6.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.38 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.97 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.24 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.38 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.03 | 4.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.39 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.92 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $445.73 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.88 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.88 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.49 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $30.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.64 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 30 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 270 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
270 | 31 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
307 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
307 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 919 | 135 |
| Potassium Chloride | Potassium Chloride | 874 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 594 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 593 | 98 |
| Gabapentin | Gabapentin | 544 | 79 |
| Furosemide | Furosemide | 506 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 449 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 448 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 111 |
| Lisinopril | Lisinopril | 394 | 99 |
| Omeprazole | Omeprazole | 382 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 70 |
| Eliquis | Apixaban | 307 | 38 |
| Allopurinol | Allopurinol | 293 | 39 |
| Farxiga | Dapagliflozin Propanediol | 270 | 31 |
| Losartan Potassium | Losartan Potassium | 260 | 76 |
| Divalproex Sodium | Divalproex Sodium | 235 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 225 | 83 |
| Trazodone Hcl | Trazodone Hcl | 223 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 60 |
| Mirtazapine | Mirtazapine | 186 | 37 |
| Tramadol Hcl | Tramadol Hcl | 182 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 26 |
| Sertraline Hcl | Sertraline Hcl | 180 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 69 |
| Glipizide Er | Glipizide | 165 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 37 |
| Methylprednisolone | Methylprednisolone | 155 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 25 |
| Alprazolam | Alprazolam | 149 | 25 |
| Carvedilol | Carvedilol | 148 | 44 |
| Metformin Hcl Er | Metformin Hcl | 148 | 40 |
| Metformin Hcl | Metformin Hcl | 144 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 30 |
| Famotidine | Famotidine | 136 | 41 |
| Ozempic | Semaglutide | 134 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 25 |
| Simvastatin | Simvastatin | 131 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 130 | 16 |
| Meloxicam | Meloxicam | 124 | 33 |
| Clonazepam | Clonazepam | 120 | 23 |
| Donepezil Hcl | Donepezil Hcl | 112 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 33 |
| Lorazepam | Lorazepam | 106 | 19 |
| Sucralfate | Sucralfate | 106 | suppressed |
| Gemtesa | Vibegron | 104 | suppressed |
| Olanzapine | Olanzapine | 101 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 16 |
| Memantine Hcl | Memantine Hcl | 97 | 13 |
| Spironolactone | Spironolactone | 97 | 20 |
| Xarelto | Rivaroxaban | 97 | suppressed |
| Haloperidol | Haloperidol | 96 | suppressed |
| Levetiracetam | Levetiracetam | 91 | suppressed |
| Baclofen | Baclofen | 87 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 16 |
| Prednisone | Prednisone | 86 | 36 |
| Benztropine Mesylate | Benztropine Mesylate | 82 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 18 |
| Primidone | Primidone | 80 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 79 | 15 |
| Montelukast Sodium | Montelukast Sodium | 79 | 23 |
| Celecoxib | Celecoxib | 78 | 26 |
| Lithium Carbonate | Lithium Carbonate | 78 | suppressed |
| Glipizide | Glipizide | 77 | 15 |
| Bumetanide | Bumetanide | 74 | 13 |
| Diazepam | Diazepam | 74 | 11 |
| Warfarin Sodium | Warfarin Sodium | 71 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 68 | 18 |
| Valsartan | Valsartan | 67 | 24 |
| Buspirone Hcl | Buspirone Hcl | 66 | 18 |
| Chlorthalidone | Chlorthalidone | 64 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 22 |
| Benazepril Hcl | Benazepril Hcl | 54 | 11 |
| Carbamazepine | Carbamazepine | 54 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 53 | suppressed |
| Lovastatin | Lovastatin | 52 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 13 |
| Nitroglycerin | Nitroglycerin | 49 | 23 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 13 |
| Risperidone | Risperidone | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 18 |
| Digoxin | Digoxin | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Nystatin | Nystatin | 39 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Azithromycin | Azithromycin | 35 | 23 |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 17 |
| Linzess | Linaclotide | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 13 |
| Levofloxacin | Levofloxacin | 32 | 27 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 30 | 30 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Lacosamide | Lacosamide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 26 |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Colchicine | Colchicine | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 13 |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Zonisamide | Zonisamide | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Estradiol | Estradiol | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Nabumetone | Nabumetone | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Dronabinol | Dronabinol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $445.73 · 24 records | Novo Nordisk Inc | ABRYSVO, BRILINTA, Barostim Neo System, CAMZYOS, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error